for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead quarterly revenue rises 26% on remdesivir sales

Feb 4 (Reuters) - Gilead Sciences Inc posted a 26% rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.

Remdesivir brought in $1.9 billion in the fourth quarter ended Dec. 31, above analysts’ estimates of $1.34 billion, according to Refinitiv IBES data. (Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D’Silva)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up